An integrated approach for tailored treatment in breast cancer

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Awada, A ^a   de Castro Jr , G ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FULVESTRANT; LAPATINIB; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DNA REPLICATION; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; HEART DISEASE; HIGH RISK PATIENT; HUMAN; IMAGING SYSTEM; MEDICAL TECHNOLOGY; OSTEOPOROSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 21344448653     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi722     Document Type: Article

References (49)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
2. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
3. Simpson JF, Gray R, Dressler LG et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000; 18: 2059-2069.
4. Bull SB, Ozcelik H, Pinnaduwage D et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004; 22: 86-96.
5. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
6. Poole CJ, Earl HM, Dunn JA et al. NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequencial ECMF. Proc Am Soc Clin Oncol 2003; 22: 4: (Abstr 13).
7. Levine MN, Bramwell VH, Pritchard KI et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-2658.
8. Hutchins L, Green S, Ravdin P et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients: First results of Intergroup trial INT 0102. Proc Am Soc Clin Oncol 1998; 17a: 1a (Abstr 2).
9. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998.
10. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061-1067.
11. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with antracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
12. Nabholtz JM, Pienkowski T, Mackey J et al. Phase III trial comparing TAC (docetaxel, doxorubicin, and cyclophosphamide) with FAC (fluorouracil, doxorubicin, and cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 2002; 21: 36a (Abstr 141).
13. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
14. Mamounas EP, Bryant J, Lembersky BC et al. Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 2003; 22: 4 (Abstr 12).
15. Roché H, Fumoleau P, Spielmann M et al. Five years analysis of the PACS01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004; 88 (Suppl 1): S16 (Abstr 27).
16. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of the Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
17. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-79.
18. Desmedt C, Tanner M, Angelo DL et al. p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel. Breast Cancer Res Treat 2004; 88 (Suppl 1): S52 (Abstr 1034).
19. Kamath K, Wilson L, Cabral F et al. beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280:12902-12907.
20. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
21. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48(24 Pt 1): 7067-7071.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
23. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
24. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
25. Coombes RC, Hall E, Snowdon CF et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two or three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 2004; 88 (Suppl 1): S7 (Abstr 3).
26. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
27. Jakesz R, Kaufmann M, Gnant M et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004; 88 (Suppl 1): S7 (Abstr 2).
28. Boccardo F, Rubagotti A, Amoroso D et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; 83 (Suppl 1): S6 (Abstr 3).
29. de Castro G Jr. ATAC trial update. Lancet 2005; 365:1225.
30. Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003; 63: 6523-6531.
31. Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003; 9 (1 Pt 2): 511S-515S.
32. Schiff R, Massarweh S, Shou J et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003; 9 (1 Pt 2): 447S-454S.
33. Ellis MJ, Coop A, Singh B et al. Letrozol is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 - and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
34. Nabholtz JM, Buzdar A, Pollack M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter trial. J Clin Oncol 2000; 18: 3758-3767.
35. Bonneterre J, Thuerlimann B, Robertson J et al. Anatrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 2000; 18: 3748-3757.
36. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozol versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
37. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398.
38. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
39. Extra JM, Cognetti F, Chan S et al. Randomized phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. Eur J Cancer 2003; 1 (Suppl): S202.
40. Tedesco KL, Thor AD, Johnson DH et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004; 22: 1071-1077.
41. Lai R, Dang CT, Malkin MG et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101: 810-816.
42. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
43. Cook GJ. Oncological molecular imaging: nuclear medicine techniques. Br J Radiol 2003; 76 (Spec No. 2): S152-S158.
44. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol 2003; 76 (Spec No. 2): S128-S138.
45. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
46. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
47. Yamamoto N, Tamura T, Murakami H et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005; 23: 1061-1069.
48. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95 (Suppl 2): 2S-4S.
49. Cook DJ, Guyatt GH, Laupacis A et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102 (Suppl 4): 305S-311S.